Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Neoadjuvant treatment is recommended for large GISTs due to their friability and risk of extensive operations; however, studies on the indications and long-term results of this approach are lacking.
Methods: Patients with large (≥ 10 cm) gastric GISTs were enrolled from multiple centers in Korea and Japan after a pathologic confirmation of c-KIT ( +) GISTs. Imatinib (400 mg/d) was given for 6-9 months preoperatively, and R0 resection was intended. Postoperative imatinib was given for at least 12 months and recommended for 3 years.
Results: A total of 56 patients were enrolled in this study, with 53 patients receiving imatinib treatment at least once and 48 patients undergoing R0 resection. The 5-year overall survival and progression-free survival rates were 94.3% and 61.6%, respectively. Even patients with stable disease by RECIST criteria responded well to preoperative imatinib treatment and could undergo R0 resection, with most being evaluated as partial response by CHOI criteria. The optimal reduction in tumor size was achieved with preoperative imatinib treatment for 24 weeks or more. No resumption of imatinib treatment was identified as an independent prognostic factor for recurrence after R0 resection. No additional size criteria for a higher risk of recurrence were identified in this cohort with a size of 10 cm or more.
Conclusions: Neoadjuvant imatinib treatment is an effective treatment option for gastric GISTs 10 cm or larger. Postoperative imatinib treatment is recommended even after R0 resection to minimize recurrence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10120-023-01406-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unveiling the impact of adherence: imatinib plasma levels and survival in postoperative gastrointestinal stromal tumor (GIST) patients.
Br J Cancer
September 2025
Department of Pharmacy, the First Affiliated Hospital of Ningbo University, Zhejiang, China.
Background: Adherence to imatinib may be even more limited in the adjuvant setting, as patients receiving adjuvant imatinib often do not experience disease symptoms after tumor removal. This real-world study aimed to gain insight into adherence to imatinib and the effect of adherence on treatment outcomes.
Methods: Postoperative GIST patients who visited the speciality clinic between January 2021 and September 2024 were included in the study.
Growth factors involved in vascular remodeling in pulmonary arterial hypertension.
J Smooth Muscle Res
September 2025
Department of Physiology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi 480-1195, Japan.
Pulmonary arterial hypertension (PAH) is a rare and fatal cardiovascular disease characterized by pulmonary vascular remodeling, leading to a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure (PAP). Elevated PAP induces right ventricular hypertrophy and eventually progresses to right heart failure. Pulmonary vascular remodeling is primarily caused by the excessive proliferation and migration of pulmonary arterial smooth muscle cells (PASMCs) in the medial layer.
View Article and Find Full Text PDFCase Report: Dramatic response to entritinib in a patient with gastrointestinal stromal tumor positive for fusion.
Front Oncol
August 2025
Department of Internal Medicine, Shaanxi Provincial Cancer Hospital, Xi'an, Shaanxi, China.
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, with proto-oncogene, receptor tyrosine kinase (c-kit), or PDGFRα mutations detected in around 85% of cases. GISTs without c-kit or platelet-derived growth factor receptor alpha (PDGFRα) mutations are considered wild-type (WT). Recently, some molecular alterations, including neurotrophic tyrosine receptor kinase (NTRK) fusions, have been reported in very few cases of WT GISTs.
View Article and Find Full Text PDFBilateral breast metastases from rectal malignant melanoma: case report and literature review.
Front Oncol
August 2025
Department of Oncology, Deyang People's Hospital, Deyang, Sichuan, China.
Rectal melanoma is an extremely rare and highly aggressive disease, and rectal melanoma metastasis to the breast is rare. This is a 48-year-old female who presented with rectal melanoma carcinoma Following the diagnosis of locally advanced rectal cancer (TxN3M0), she received chemotherapy, immunotherapy with radiotherapy, and metastases to the lung, bone and vulvar developed during the therapy. After one year of treatment, the patient developed bilateral breast metastases.
View Article and Find Full Text PDFImpact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations.
Blood
September 2025
Centre for Cancer Biology, SA Pathology, Adelaide, Australia.
Genomic profiling in chronic-phase chronic myeloid leukemia (CP-CML) patients demonstrated somatic variants in blood cancer-related genes (CGVs) and rearrangements associated with the formation of the Philadelphia-chromosome (Ph-associated rearrangements) at diagnosis, collectively termed additional genetic abnormalities (AGA). AGAs had a negative impact on failure-free survival and molecular response in imatinib-treated patients. We investigated whether treatment with more potent therapies could overcome the negative impact of AGAs at diagnosis.
View Article and Find Full Text PDF